Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00668525 · ClinicalTrials.gov registry record · Phase 3
Escitalopram in Adult Patients With Major Depressive Disorder
A Phase 3 study of Major Depressive Disorder, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 3
- Development phase
- 877
- Enrollment target
- 20
- Study locations
NCT00668525 is a Phase 3 study of Major Depressive Disorder that has completed, run by Forest Laboratories. The registered enrollment target is 877 participants, above the 374-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (134% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT00668525, a Phase 3 study of Major Depressive Disorder, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 877 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a short-term study to evaluate the efficacy, safety, and tolerability of escitalopram in adult patients (18 to 65 years of age) with moderate to severe depression. Patients completing the study may be eligible to enter a long-term open-label extension study with escitalopram.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Escitalopram
Study Locations (20)
California
- Forest Investigative Site - Arcadia
- Forest Investigative Site - Encino
- Forest Investigative Site - Garden Grove
- Forest Investigative Site - Irvine
- Forest Investigative Site - Los Alamitos
Florida
- Forest Investigative Site - Bradenton
- Forest Investigative Site - Jacksonville
- Forest Investigative Site - Orlando
- Forest Investigative Site - West Palm Beach
Maryland
- Forest Investigative Site - Baltimore
- Forest Investigative Site - Glen Burnie
- Forest Investigative Site - Rockville
Kansas
- Forest Investigative Site - Newton
- Forest Investigative Site - Overland
Arizona
- Forest Investigative Site - Phoenix
Colorado
- Forest Investigative Site - Denver
District of Columbia
- Forest Investigative Site - Washington D.C.
Georgia
- Forest Investigative Site - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 877 participants |
| Start Date | 2008-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00668525
The ClinicalTrials.gov registry entry for NCT00668525 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 877 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 374-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (134% higher). The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00668525 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Maryland.
Frequently Asked Questions
What is clinical trial NCT00668525 about?
NCT00668525 is a clinical study titled "Escitalopram in Adult Patients With Major Depressive Disorder". This is a short-term study to evaluate the efficacy, safety, and tolerability of escitalopram in adult patients (18 to 65 years of age) with moderate to severe depression. Patients completing the study may be eligible to enter a long-term open-label extension study with escitalopram.
What is the current status of trial NCT00668525?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 877 participants. The study started on 2008-04.
What conditions does trial NCT00668525 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT00668525?
The interventions under investigation include: Placebo (DRUG), Escitalopram (DRUG).
Who is sponsoring clinical trial NCT00668525?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00668525 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
-
Study to Assess the Safety and Effectiveness of NMRA-335140-501
RECRUITING · Phase 3
-
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
-
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
RECRUITING · Phase 3
-
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
RECRUITING · Phase 3
-
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.